Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Nausea 5Vomiting 4Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Weight Loss 1Radiation Injuries 1Neoplasms, Germ Cell and Embryonal 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1Anorexia Nervosa with Significantly Low Body Weight 1Anorexia 1

Interventions

Oxaliplatin 166Capecitabine 112Fluorouracil 95Docetaxel 85Cisplatin 84S 1 (combination) 83Leucovorin 64Paclitaxel 58Irinotecan 56pembrolizumab 36sintilimab 34Trastuzumab 34apatinib 30Bevacizumab 21Surgical Procedures, Operative 19Radiotherapy 19titanium silicide 17camrelizumab 17Nivolumab 17Ramucirumab 16Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 14Folfox protocol 14Epirubicin 14tislelizumab 13Neoadjuvant Therapy 12Cetuximab 12XELOX 10Tegafur 10Carboplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Stomach Neoplasms × Olanzapine × Clear all
NCT07581405 2026-05-12

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

University of Illinois at Chicago

Phase 2 Not yet recruiting
26 enrolled
Gastrointestinal

Stomach Neoplasms

NCT03575637 2018-07-03

Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer

Peking University

Phase 2 Unknown
180 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡